USPTO serial 79338772
CCRM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 28, 2023
- Examiner
- FOSDICK, GEOFFREY A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CCRM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Centre for Commercialization of Regenerative Medicine
CA
Other trademarks owned by Centre for Commercialization of Regenerative Medicine
Centre for Commercialization of Regenerative Medicine
CA
Other trademarks owned by Centre for Commercialization of Regenerative Medicine
Centre for Commercialization of Regenerative Medicine
CA
Other trademarks owned by Centre for Commercialization of Regenerative Medicine
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David J. Davis
David J. Davis Baker & McKenzie LLP300 E. Randolph StreetSuite 5000Chicago, IL 60601Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business planning; providing market intelligence services | ACTIVE | — |
| 040 | Custom manufacture of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms | ACTIVE | — |
| 042 | Development of pharmaceutical preparations and medicines; pharmaceutical research and development; research and development of new biotechnological products for others for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; development of new biotechnological products for others for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; providing medical and scientific research information in the field of clinical trials; medical and scientific research, namely, conducting clinical trials for others; genetic testing for scientific research purposes in the field of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; scientific research in the field of genetic engineering, namely, research of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms | ACTIVE | — |
| 045 | Reviewing standards and practices to assure compliance with regulations related to the research, development, manufacture and sale of products in the health care and medical fields and the administration of health care services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Centre for Commercialization of Regenerative Medicine
- Other trademarks owned by Centre for Commercialization of Regenerative Medicine
- Other trademarks owned by Centre for Commercialization of Regenerative Medicine
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named CCRM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Apr 8, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 2, 2024 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Mar 2, 2024 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Feb 28, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 28, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 28, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 16, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 27, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 12, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 12, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 12, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 23, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 23, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 23, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 20, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 9, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 8, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 8, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 7, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 4, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 9, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 9, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 31, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 26, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 21, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |